ClinicalTrials.gg
Status unknownNCT03487055Updated Apr 3, 2018

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

A Phase 1 interventional study of TK006 in Breast Cancer, sponsored by Jiangsu T-Mab Biopharma Co.,Ltd. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by Jiangsu T-Mab Biopharma Co.,Ltd (part of Mabwell (Shanghai) Bioscience Co., Ltd.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open labelled study. It was designed to evaluate the safety of multiple-dosing of TK006 in patients with breast cancer-related bone metastases. This trial is the extension of a core study: Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases (NCT 03239756).

Read the detailed description

This trial is the extension of a core study: Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases (NCT 03239756). It's an open labelled study, aimed at evaluating the safety of repeated administration of TK006 in patients with breast cancer-related bone metastases. The qualified subjects would be those completed the entire observation in either 60 mg, 120 mg or 180 mg single dose arm at the core study. Also, these patients should be well-tolerated with TK006 at the core study and are deemed to further benefit from this extension phase estimated by the researcher and sponsor. The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.

Only safety profile and immunogenicity assessment would be assessed in this extension stage, and no further study on pharmacokinetics and pharmacodynamics would be done.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 30 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Jiangsu T-Mab Biopharma Co.,Ltd is the lead sponsor of 8 studies on the registry; none are open to participants now.

First submitted after Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients provide written voluntarily.
  2. 18\~65 years old, male or female.
  3. Patients who completed the entire observation in either 60 mg, 120 mg or 180 mg single dose arm at the core phase (NCT 03239756). Also, these patients should be well-tolerated with TK006 and would further benefit from continued treatment estimated by the researcher and sponsor.
  4. ≤2.
  5. Albumin-adjusted calcium≥2.0mmol/L, ≤2.9mmol/ L.

Exclusion criteria

Exclusion Criteria:

  1. Women in pregnancy or nursing.
  2. Central nervous system that is symptomatic or require treatment.
  3. Patients with grade III or IV adverse events considered related to TK006 at the core phase (NCT 03239756).
  4. Patients with important organs dysfunction and not suitable for further treatment with TK006 judged by the researcher.
  5. Imaging confirmed progression in bone metastasis compared with core phase (NCT 03239756).
  6. Previous or existing osteomyelitis or osteonecrosis of jaw, toothache or jaw diseases which are in active or require invasive operations, unhealed wound of oral surgery, or planned invasive dental operations during this trial.
  7. Patients who have been selected for the study of other test devices or test medicine.
  8. Other situations which are not suitable for participation judged by the researcher.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    treatment group

    The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.

    Biological: TK006

Interventions

  • BiologicalTK006

    Subcutaneous injection in the upper arm

    Also known as: fully human monoclonal anti-RANKL antibody

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events(AEs)which are related to TK006 treatment throughout the study

    Adverse events refer to any treatment related abnormality with clinical significance identified by means of vital signs examination, physical check-up, twelve leads electrocardiogram inspection and laboratory tests throughout the study. Adverse events reported by subjects would also be recorded in the entire trial. All these abnormal cases described above would be reported as incidence of adverse events.

    Time frame: 85 days

Secondary outcomes

  1. immunogenicity

    Neutralization antibody of TK006 would be detected on the day 0 (before dosing), day 28 (before dosing) and day 84.

    Time frame: 85 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2018; primary completion for May 2019, 12 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2018
First posted
Apr 3, 2018
StartEst.
May 2018
Primary completionEst.
May 2019
CompletionEst.
May 2019
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03487055
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
May 2018 (estimated)
Primary completion
May 2019 (estimated)
Completion
May 2019 (estimated)
Last update
Apr 3, 2018

Study contacts

Yu M X
Contact
yumingxia@sh-qingfeng.net
15021830072
jiang H B
Contact
jianghaibiao@sh-qingfeng.net
13062892252
jiang H Y
study director · Jiangsu T-Mab Biopharma Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TK-006

Start the discussion